Form 4: Forbion Funds Reduce Stake in NewAmsterdam Pharma Co N.V. (NAMS) Through Multiple Transactions

Forbion-affiliated entities executed multiple sales of NewAmsterdam Pharma Co N.V. ordinary shares between December 16 and December 17, 2024, reducing their overall holdings.

Summary

• ForGrowth NAP B.V., along with affiliated Forbion funds, reported the sale of NewAmsterdam Pharma Co N.V. (NAMS) ordinary shares.
• The transactions occurred on December 16 and 17, 2024.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 28, 2024.
• On December 16, 2024, 1,096 shares were sold at $25 per share.
• On December 17, 2024, two transactions occurred: 66,648 shares were sold at a weighted average price of $25.6019, and 47,736 shares were sold at a weighted average price of $26.4463.
• The reported sales resulted in a decrease in the number of ordinary shares beneficially owned by ForGrowth NAP B.V.
• Following these transactions, ForGrowth NAP B.V. beneficially owns 11,009,230 ordinary shares.
• The shares are held directly by ForGrowth on behalf of Forbion Growth Opportunities Fund I Cooperatief U.A. (652,173 shares) and indirectly through PoolCo, allocated to ForGrowth, with beneficial ownership split between Forbion Growth I (4,182,774 shares) and Forbion Capital Fund IV Cooperatief U.A. (6,174,283 shares).

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing trading plan. There's no inherent positive or negative signal, but the market's reaction will depend on its interpretation of the reduced stake.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, which can provide transparency and reduce concerns about insider trading.

Negatives

• The sales represent a reduction in the stake held by Forbion-affiliated entities, which could be interpreted negatively by the market.

Risks

• Continued sales by major shareholders could put downward pressure on the stock price.
• The market may react negatively to the reduced ownership by Forbion funds, potentially impacting investor confidence.

Future Outlook

The document does not contain specific forward-looking statements beyond the ongoing execution of the Rule 10b5-1 trading plan.

Industry Context

Form 4 filings are standard disclosures for significant shareholders, providing transparency into their trading activities. The pharmaceutical industry is often subject to scrutiny regarding insider trading, making adherence to Rule 10b5-1 plans important.

Comparison to Industry Standards

• Form 4 filings are a standard practice across all publicly traded companies, including pharmaceutical firms like Amgen (AMGN), Pfizer (PFE), and Johnson & Johnson (JNJ).
• The use of Rule 10b5-1 trading plans is also common among executives and major shareholders in these companies to manage their stock sales in compliance with insider trading regulations.
• The size and frequency of the transactions are typical for institutional investors managing their positions in a company.

Stakeholder Impact

• Shareholders may react to the reduced stake held by Forbion funds.
• The impact on employees, customers, suppliers, and creditors is likely minimal, as the transactions do not directly affect the company's operations.

Key Dates